1. Home
  2. RGNT vs ECOR Comparison

RGNT vs ECOR Comparison

Compare RGNT & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$6.90

Market Cap

36.9M

Sector

Health Care

ML Signal

N/A

Logo electroCore Inc.

ECOR

electroCore Inc.

HOLD

Current Price

$4.71

Market Cap

39.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGNT
ECOR
Founded
2004
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.9M
39.6M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
RGNT
ECOR
Price
$6.90
$4.71
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$25.50
AVG Volume (30 Days)
33.4K
38.4K
Earning Date
02-08-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$29,835,000.00
Revenue This Year
N/A
$28.61
Revenue Next Year
N/A
$41.21
P/E Ratio
N/A
N/A
Revenue Growth
N/A
27.90
52 Week Low
$5.75
$4.16
52 Week High
$7.70
$19.49

Technical Indicators

Market Signals
Indicator
RGNT
ECOR
Relative Strength Index (RSI) N/A 43.27
Support Level N/A $4.41
Resistance Level N/A $5.00
Average True Range (ATR) 0.00 0.25
MACD 0.00 0.01
Stochastic Oscillator 0.00 30.77

Price Performance

Historical Comparison
RGNT
ECOR

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Share on Social Networks: